loading
Oruka Therapeutics Inc stock is traded at $11.56, with a volume of 243.48K. It is down -11.62% in the last 24 hours and down -39.13% over the past month. Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$13.08
Open:
$13.01
24h Volume:
243.48K
Relative Volume:
0.87
Market Cap:
$457.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-14.05%
1M Performance:
-39.13%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$11.11
$13.47
1-Week Range:
Value
$11.11
$15.10
52-Week Range:
Value
$10.95
$31.13

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name
Name
Oruka Therapeutics Inc
Name
Phone
650-606-7910
Name
Address
855 OAK GROVE AVE., MENLO PARK
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
ORKA's Discussions on Twitter

Compare ORKA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ORKA
Oruka Therapeutics Inc
11.62 457.78M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.57 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
716.57 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
653.51 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
274.50 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.28 28.75B 3.30B -501.07M 1.03B -2.1146

Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-25 Initiated Wolfe Research Outperform
Oct-11-24 Initiated Stifel Buy
Oct-07-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated Leerink Partners Outperform
Sep-16-24 Initiated TD Cowen Buy
Sep-13-24 Initiated Jefferies Buy
Feb-27-18 Initiated Ascendiant Capital Markets Buy
Oct-09-13 Initiated Dawson James Buy
View All

Oruka Therapeutics Inc Stock (ORKA) Latest News

pulisher
06:32 AM

Oruka Therapeutics inks exclusive license deal with Paragon - MSN

06:32 AM
pulisher
Feb 06, 2025

Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpHere's What Happened - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Wolfe Research Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Feb 06, 2025
pulisher
Feb 06, 2025

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wolfe Research - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

Oruka Therapeutics (NASDAQ:ORKA) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN

Feb 05, 2025
pulisher
Feb 04, 2025

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 04, 2025
pulisher
Feb 04, 2025

Wolfe Research Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN

Feb 04, 2025
pulisher
Feb 02, 2025

Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Oruka Therapeutics (ORKA) Projected to Post Earnings on Thursday - Defense World

Jan 30, 2025
pulisher
Jan 21, 2025

Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17 - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Time to Sell? - Defense World

Jan 19, 2025
pulisher
Jan 17, 2025

Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week LowWhat's Next? - MarketBeat

Jan 17, 2025
pulisher
Jan 13, 2025

Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8%Should You Sell? - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World

Jan 13, 2025
pulisher
Jan 10, 2025

Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year LowWhat's Next? - MarketBeat

Jan 10, 2025
pulisher
Jan 07, 2025

Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8%What's Next? - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Oruka Therapeutics (NASDAQ:ORKA) versus Myriad Genetics (NASDAQ:MYGN) Head to Head Comparison - Defense World

Jan 07, 2025
pulisher
Dec 30, 2024

Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week LowShould You Sell? - MarketBeat

Dec 30, 2024
pulisher
Dec 27, 2024

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus Target Price from Analysts - MarketBeat

Dec 27, 2024
pulisher
Dec 27, 2024

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Dec 27, 2024
pulisher
Dec 26, 2024

Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.2%Time to Sell? - MarketBeat

Dec 26, 2024
pulisher
Dec 25, 2024

Critical Contrast: BG Medicine (OTCMKTS:BGMD) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Dec 25, 2024
pulisher
Dec 24, 2024

Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Dec 24, 2024
pulisher
Dec 21, 2024

Franklin Resources Inc. Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

H.C. Wainwright bullish on Oruka stock after early clinical success for ORKA-001 - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

Oruka Therapeutics' (ORKA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 - Yahoo Finance

Dec 20, 2024
pulisher
Dec 19, 2024

Oruka Therapeutics enters exclusive licensing deal with Paragon - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.7%Should You Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - The Manila Times

Dec 19, 2024
pulisher
Dec 19, 2024

Oruka Therapeutics Announces First Participants Dosed in - GlobeNewswire

Dec 19, 2024
pulisher
Dec 19, 2024

Oruka Therapeutics Launches Phase 1 Trial of Revolutionary Long-Acting Psoriasis Treatment ORKA-001 - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

Wellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World

Dec 19, 2024
pulisher
Dec 19, 2024

Wellington Management Group LLP Takes $2.01 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times

Dec 18, 2024
pulisher
Dec 18, 2024

Oruka Therapeutics to Join Prestigious Nasdaq Biotechnology Index in Major Milestone - StockTitan

Dec 18, 2024
pulisher
Dec 16, 2024

Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume IncreaseShould You Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 13, 2024

The Manufacturers Life Insurance Company Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World

Dec 13, 2024
pulisher
Dec 13, 2024

The Manufacturers Life Insurance Company Invests $1.04 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance

Dec 11, 2024
pulisher
Dec 10, 2024

Frazier Life Sciences Management L.P. Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat

Dec 10, 2024
pulisher
Dec 10, 2024

Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat

Dec 10, 2024

Oruka Therapeutics Inc Stock (ORKA) Financials Data

There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Oruka Therapeutics Inc Stock (ORKA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
JANUS HENDERSON GROUP PLC
10% Owner
Jul 24 '24
Buy
3.20
189,856
606,873
2,081,168
JANUS HENDERSON GROUP PLC
10% Owner
Jul 25 '24
Buy
3.05
30,227
92,292
2,111,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 03 '24
Buy
3.55
166,042
589,565
1,648,577
JANUS HENDERSON GROUP PLC
10% Owner
Jul 11 '24
Buy
3.45
94,537
326,304
1,891,312
JANUS HENDERSON GROUP PLC
10% Owner
Jul 10 '24
Buy
3.46
55,463
192,130
1,796,775
JANUS HENDERSON GROUP PLC
10% Owner
Jul 08 '24
Buy
3.46
47,492
164,190
1,724,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 05 '24
Buy
3.43
28,326
97,065
1,676,903
JANUS HENDERSON GROUP PLC
10% Owner
Jul 09 '24
Buy
3.43
16,917
58,091
1,741,312
$80.25
price down icon 0.67%
$20.11
price down icon 2.91%
$348.43
price down icon 1.59%
$4.73
price down icon 7.14%
biotechnology ONC
$222.81
price down icon 2.73%
$118.25
price down icon 1.43%
Cap:     |  Volume (24h):